Kristen Ward received her PharmD from the University Of Michigan College Of Pharmacy in 2014, and went on to complete a three year fellowship in precision medicine research under the mentorship of Dr. Vicki Ellingrod. She joined the College of Pharmacy as a Clinical Assistant Professor in 2018, and currently has a clinical role in ambulatory psychiatry and pharmacogenomics implementation. Her research goals are to apply precision medicine techniques, such as metabolomics and pharmacogenomics, to improve medication outcomes for patients with serious mental illness.
- Mechanisms and risk factors underlying antipsychotic adverse drug events
- The application of pharmacogenomics to improve the safety and efficacy of psychotropic medications
- Pharmacogenomics implementation and education
- Ward KM, Yeoman L, McHugh C, et al. Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia. Pharmacotherapy 2018; 38: 638–650.
- Burghardt K, Ward K, Sanders E, et al. Atypical Antipsychotics and the Human Skeletal Muscle Lipidome. Metabolites 2018; 8: 64.
- Ward K, Citrome L. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy. Expert Opinion on Investigational Drugs 2020; 29: 245–257.
- Castellani LN, Costa-Dookhan K, McIntyre W, et al. Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism. J Psychiatry Brain Sci; 4. Epub ahead of print 2019. DOI: 10.20900/jpbs.20190013.